share_log

HC Wainwright & Co. Initiates Coverage On Candel Therapeutics With Buy Rating, Announces Price Target of $11

Benzinga Real-time News ·  Dec 2, 2022 06:32

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment